Research Index

Every peptide in the library, what the evidence currently looks like, and where to read it. Each row opens live searches on PubMed, Europe PMC, and ClinicalTrials.gov, plus a link to the full profile.

  • BPC-157: Extensive animal data, very limited human trial data. Not approved as a medicine in the US. Sold for research purposes only.
  • TB-500: Animal and preclinical data. Banned by WADA for competitive athletes. Research use only.
  • Semaglutide: FDA approved as a prescription medicine under brand names. Compounded and research-grade versions are not the approved product.
  • Tirzepatide: FDA approved as a prescription medicine. Research-grade material is not the approved product.
  • Retatrutide: Investigational. Not approved for human use in any country. Long-term safety is unknown.
  • Ipamorelin: Not approved as a medicine. Widely used in research settings.
  • CJC-1295 (no DAC): Not approved as a medicine. Research use only.
  • Tesamorelin: FDA approved for HIV-associated lipodystrophy. Other uses are off label or research.
  • AOD-9604: Human trials for obesity did not beat placebo on weight at the endpoints tested. Research use only.
  • GHK-Cu: Well documented in dermatology literature for topical use. Injectable use is research only.
  • NAD+: Human research is early. Oral precursors such as NMN and NR have more published data.
  • Epitalon: Most data comes from a small number of Russian research groups. Independent replication is thin.
  • Semax: Registered as a medicine in Russia. Not approved in the US or EU. Western trial data is sparse.
  • Selank: Registered in Russia for anxiety. Limited Western data.
  • PT-141: FDA approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women.
  • Kisspeptin-10: Active human research in fertility clinics. Not an approved product.
  • Thymosin Alpha-1: Approved as a medicine in many countries for hepatitis B and C. Not approved in the US.
  • KPV: Animal and cell research. No approved human product.
  • MOTS-c: Animal and early human research. Not approved.
  • Hexarelin: Not approved. Desensitisation with continuous use is documented.
  • IGF-1 LR3: Not approved. Banned in tested sport. One of the higher risk compounds in circulation.
  • Melanotan II: Not approved anywhere. Regulators in several countries have issued warnings.
  • LL-37: Preclinical and early research. No approved product.
  • DSIP: Old research base, limited modern human trials. Research use only.